About
Technology
Issues
FAQ
Links
Official Page
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.